nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—prostate cancer	0.27	1	CbGaD
Maraviroc—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0816	0.207	CbGbCtD
Maraviroc—CYP3A4—Bicalutamide—prostate cancer	0.0429	0.109	CbGbCtD
Maraviroc—CYP3A4—Estramustine—prostate cancer	0.0399	0.101	CbGbCtD
Maraviroc—CYP3A4—Flutamide—prostate cancer	0.0355	0.09	CbGbCtD
Maraviroc—CYP3A4—Abiraterone—prostate cancer	0.0355	0.09	CbGbCtD
Maraviroc—CYP3A4—Cabazitaxel—prostate cancer	0.0263	0.0666	CbGbCtD
Maraviroc—CYP3A4—Estrone—prostate cancer	0.0257	0.0651	CbGbCtD
Maraviroc—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0229	0.058	CbGbCtD
Maraviroc—CYP3A4—Conjugated Estrogens—prostate cancer	0.0168	0.0426	CbGbCtD
Maraviroc—CYP3A4—Mitoxantrone—prostate cancer	0.0153	0.0387	CbGbCtD
Maraviroc—CYP3A4—Estradiol—prostate cancer	0.0148	0.0374	CbGbCtD
Maraviroc—CYP3A4—Prednisone—prostate cancer	0.0127	0.0321	CbGbCtD
Maraviroc—CYP3A4—Etoposide—prostate cancer	0.00963	0.0244	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—prostate cancer	0.00882	0.0223	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—prostate cancer	0.00657	0.0166	CbGbCtD
Maraviroc—CCR5—renal system—prostate cancer	0.00237	0.505	CbGeAlD
Maraviroc—CCR5—lymph node—prostate cancer	0.00111	0.236	CbGeAlD
Maraviroc—CYP3A4—urine—prostate cancer	0.000977	0.208	CbGeAlD
Maraviroc—CYP3A4—renal system—prostate cancer	0.000239	0.0509	CbGeAlD
Maraviroc—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.84e-05	0.00061	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.83e-05	0.000609	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADRB2—prostate cancer	5.83e-05	0.000608	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.76e-05	0.000602	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—JAK2—prostate cancer	5.75e-05	0.0006	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.73e-05	0.000599	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAP2K1—prostate cancer	5.73e-05	0.000598	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.7e-05	0.000595	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—prostate cancer	5.69e-05	0.000594	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VAV3—prostate cancer	5.68e-05	0.000593	CbGpPWpGaD
Maraviroc—CCR5—Disease—BAD—prostate cancer	5.64e-05	0.000588	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.63e-05	0.000587	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFBR2—prostate cancer	5.6e-05	0.000585	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.55e-05	0.000579	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ITPR1—prostate cancer	5.51e-05	0.000576	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.49e-05	0.000574	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—prostate cancer	5.46e-05	0.00057	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—prostate cancer	5.46e-05	0.00057	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.43e-05	0.000567	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.43e-05	0.000567	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGF—prostate cancer	5.4e-05	0.000563	CbGpPWpGaD
Maraviroc—CCR5—Disease—IRS1—prostate cancer	5.4e-05	0.000563	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	5.36e-05	0.000559	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	5.36e-05	0.000559	CbGpPWpGaD
Maraviroc—Pancytopenia—Doxorubicin—prostate cancer	5.28e-05	0.000225	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1R—prostate cancer	5.27e-05	0.00055	CbGpPWpGaD
Maraviroc—Renal failure—Epirubicin—prostate cancer	5.27e-05	0.000224	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Etoposide—prostate cancer	5.26e-05	0.000224	CcSEcCtD
Maraviroc—Asthenia—Mitoxantrone—prostate cancer	5.26e-05	0.000224	CcSEcCtD
Maraviroc—Fatigue—Etoposide—prostate cancer	5.26e-05	0.000224	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—prostate cancer	5.25e-05	0.000224	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.25e-05	0.000224	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—prostate cancer	5.25e-05	0.000548	CbGpPWpGaD
Maraviroc—Cough—Capecitabine—prostate cancer	5.25e-05	0.000223	CcSEcCtD
Maraviroc—CCR5—Disease—GSK3B—prostate cancer	5.24e-05	0.000547	CbGpPWpGaD
Maraviroc—Stomatitis—Epirubicin—prostate cancer	5.22e-05	0.000222	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—prostate cancer	5.22e-05	0.000222	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—JAK2—prostate cancer	5.22e-05	0.000545	CbGpPWpGaD
Maraviroc—Constipation—Etoposide—prostate cancer	5.21e-05	0.000222	CcSEcCtD
Maraviroc—Pain—Etoposide—prostate cancer	5.21e-05	0.000222	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	5.21e-05	0.000544	CbGpPWpGaD
Maraviroc—Conjunctivitis—Epirubicin—prostate cancer	5.21e-05	0.000222	CcSEcCtD
Maraviroc—Dizziness—Estradiol—prostate cancer	5.2e-05	0.000221	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—prostate cancer	5.2e-05	0.000221	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—prostate cancer	5.17e-05	0.00022	CcSEcCtD
Maraviroc—CCR5—Disease—INS—prostate cancer	5.17e-05	0.000539	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	5.14e-05	0.000536	CbGpPWpGaD
Maraviroc—Myalgia—Capecitabine—prostate cancer	5.12e-05	0.000218	CcSEcCtD
Maraviroc—Anxiety—Capecitabine—prostate cancer	5.1e-05	0.000217	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.08e-05	0.000216	CcSEcCtD
Maraviroc—Hepatobiliary disease—Epirubicin—prostate cancer	5.07e-05	0.000216	CcSEcCtD
Maraviroc—Oedema—Docetaxel—prostate cancer	5.07e-05	0.000216	CcSEcCtD
Maraviroc—CCR5—Disease—CREBBP—prostate cancer	5.06e-05	0.000528	CbGpPWpGaD
Maraviroc—Discomfort—Capecitabine—prostate cancer	5.06e-05	0.000215	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—LPL—prostate cancer	5.05e-05	0.000528	CbGpPWpGaD
Maraviroc—Infection—Docetaxel—prostate cancer	5.03e-05	0.000214	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—prostate cancer	5.03e-05	0.000214	CcSEcCtD
Maraviroc—Diarrhoea—Mitoxantrone—prostate cancer	5.02e-05	0.000214	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—IL2—prostate cancer	5.01e-05	0.000524	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFRB—prostate cancer	5.01e-05	0.000523	CbGpPWpGaD
Maraviroc—Vomiting—Estradiol—prostate cancer	5e-05	0.000213	CcSEcCtD
Maraviroc—Agranulocytosis—Epirubicin—prostate cancer	5e-05	0.000213	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—prostate cancer	4.99e-05	0.000212	CcSEcCtD
Maraviroc—Gastrointestinal pain—Etoposide—prostate cancer	4.99e-05	0.000212	CcSEcCtD
Maraviroc—Shock—Docetaxel—prostate cancer	4.98e-05	0.000212	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—prostate cancer	4.97e-05	0.000212	CcSEcCtD
Maraviroc—Rash—Estradiol—prostate cancer	4.96e-05	0.000211	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—prostate cancer	4.96e-05	0.000518	CbGpPWpGaD
Maraviroc—Infestation NOS—Doxorubicin—prostate cancer	4.96e-05	0.000211	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—prostate cancer	4.96e-05	0.000211	CcSEcCtD
Maraviroc—Dermatitis—Estradiol—prostate cancer	4.96e-05	0.000211	CcSEcCtD
Maraviroc—Anaemia—Prednisone—prostate cancer	4.95e-05	0.000211	CcSEcCtD
Maraviroc—Headache—Estradiol—prostate cancer	4.93e-05	0.00021	CcSEcCtD
Maraviroc—Skin disorder—Docetaxel—prostate cancer	4.92e-05	0.00021	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	4.92e-05	0.000209	CcSEcCtD
Maraviroc—Oedema—Capecitabine—prostate cancer	4.91e-05	0.000209	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ITGB3—prostate cancer	4.88e-05	0.00051	CbGpPWpGaD
Maraviroc—Renal failure—Doxorubicin—prostate cancer	4.87e-05	0.000208	CcSEcCtD
Maraviroc—Infection—Capecitabine—prostate cancer	4.87e-05	0.000208	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—prostate cancer	4.86e-05	0.000207	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.84e-05	0.000506	CbGpPWpGaD
Maraviroc—Stomatitis—Doxorubicin—prostate cancer	4.83e-05	0.000206	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—prostate cancer	4.83e-05	0.000206	CcSEcCtD
Maraviroc—CCR5—Disease—MAP2K1—prostate cancer	4.83e-05	0.000504	CbGpPWpGaD
Maraviroc—Anorexia—Docetaxel—prostate cancer	4.83e-05	0.000206	CcSEcCtD
Maraviroc—Shock—Capecitabine—prostate cancer	4.83e-05	0.000206	CcSEcCtD
Maraviroc—Rhinitis—Epirubicin—prostate cancer	4.82e-05	0.000205	CcSEcCtD
Maraviroc—Abdominal pain—Etoposide—prostate cancer	4.82e-05	0.000205	CcSEcCtD
Maraviroc—Body temperature increased—Etoposide—prostate cancer	4.82e-05	0.000205	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—prostate cancer	4.82e-05	0.000205	CcSEcCtD
Maraviroc—Nervous system disorder—Capecitabine—prostate cancer	4.81e-05	0.000205	CcSEcCtD
Maraviroc—Syncope—Prednisone—prostate cancer	4.8e-05	0.000204	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CD—prostate cancer	4.8e-05	0.000501	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.79e-05	0.0005	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.78e-05	0.000499	CbGpPWpGaD
Maraviroc—Pharyngitis—Epirubicin—prostate cancer	4.77e-05	0.000203	CcSEcCtD
Maraviroc—Skin disorder—Capecitabine—prostate cancer	4.77e-05	0.000203	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—prostate cancer	4.76e-05	0.000497	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Epirubicin—prostate cancer	4.75e-05	0.000202	CcSEcCtD
Maraviroc—CCR5—Disease—SERPINE1—prostate cancer	4.75e-05	0.000496	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB3—prostate cancer	4.73e-05	0.000494	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Epirubicin—prostate cancer	4.73e-05	0.000201	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FGFR2—prostate cancer	4.73e-05	0.000493	CbGpPWpGaD
Maraviroc—Urethral disorder—Epirubicin—prostate cancer	4.72e-05	0.000201	CcSEcCtD
Maraviroc—Loss of consciousness—Prednisone—prostate cancer	4.71e-05	0.0002	CcSEcCtD
Maraviroc—Hepatobiliary disease—Doxorubicin—prostate cancer	4.69e-05	0.0002	CcSEcCtD
Maraviroc—Anorexia—Capecitabine—prostate cancer	4.68e-05	0.000199	CcSEcCtD
Maraviroc—Nausea—Estradiol—prostate cancer	4.67e-05	0.000199	CcSEcCtD
Maraviroc—Vomiting—Mitoxantrone—prostate cancer	4.66e-05	0.000198	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—prostate cancer	4.65e-05	0.000198	CcSEcCtD
Maraviroc—Convulsion—Prednisone—prostate cancer	4.64e-05	0.000198	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—prostate cancer	4.63e-05	0.000197	CcSEcCtD
Maraviroc—Rash—Mitoxantrone—prostate cancer	4.62e-05	0.000197	CcSEcCtD
Maraviroc—Dermatitis—Mitoxantrone—prostate cancer	4.62e-05	0.000197	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.62e-05	0.000197	CcSEcCtD
Maraviroc—CCR5—Disease—FGF2—prostate cancer	4.59e-05	0.00048	CbGpPWpGaD
Maraviroc—Headache—Mitoxantrone—prostate cancer	4.59e-05	0.000196	CcSEcCtD
Maraviroc—Insomnia—Docetaxel—prostate cancer	4.58e-05	0.000195	CcSEcCtD
Maraviroc—Myalgia—Prednisone—prostate cancer	4.56e-05	0.000194	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.56e-05	0.000476	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—prostate cancer	4.55e-05	0.000475	CbGpPWpGaD
Maraviroc—Paraesthesia—Docetaxel—prostate cancer	4.55e-05	0.000194	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—prostate cancer	4.55e-05	0.000194	CcSEcCtD
Maraviroc—Anxiety—Prednisone—prostate cancer	4.54e-05	0.000193	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TERT—prostate cancer	4.54e-05	0.000474	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS3—prostate cancer	4.53e-05	0.000473	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.53e-05	0.000193	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.51e-05	0.000471	CbGpPWpGaD
Maraviroc—Discomfort—Prednisone—prostate cancer	4.5e-05	0.000192	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—prostate cancer	4.5e-05	0.000191	CcSEcCtD
Maraviroc—Hypersensitivity—Etoposide—prostate cancer	4.49e-05	0.000191	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.47e-05	0.00019	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—prostate cancer	4.46e-05	0.00019	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—prostate cancer	4.46e-05	0.00019	CcSEcCtD
Maraviroc—Insomnia—Capecitabine—prostate cancer	4.44e-05	0.000189	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—prostate cancer	4.42e-05	0.000188	CcSEcCtD
Maraviroc—Paraesthesia—Capecitabine—prostate cancer	4.41e-05	0.000188	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—prostate cancer	4.4e-05	0.000188	CcSEcCtD
Maraviroc—CCR5—Disease—JAK2—prostate cancer	4.4e-05	0.00046	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Doxorubicin—prostate cancer	4.4e-05	0.000187	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Docetaxel—prostate cancer	4.37e-05	0.000186	CcSEcCtD
Maraviroc—Asthenia—Etoposide—prostate cancer	4.37e-05	0.000186	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—prostate cancer	4.37e-05	0.000186	CcSEcCtD
Maraviroc—Oedema—Prednisone—prostate cancer	4.37e-05	0.000186	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—prostate cancer	4.37e-05	0.000186	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—prostate cancer	4.36e-05	0.000186	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—prostate cancer	4.36e-05	0.000186	CcSEcCtD
Maraviroc—Nausea—Mitoxantrone—prostate cancer	4.35e-05	0.000185	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.34e-05	0.000453	CbGpPWpGaD
Maraviroc—Infection—Prednisone—prostate cancer	4.34e-05	0.000185	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HIF1A—prostate cancer	4.34e-05	0.000453	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Epirubicin—prostate cancer	4.34e-05	0.000185	CcSEcCtD
Maraviroc—Pain—Docetaxel—prostate cancer	4.33e-05	0.000184	CcSEcCtD
Maraviroc—Constipation—Docetaxel—prostate cancer	4.33e-05	0.000184	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.32e-05	0.000451	CbGpPWpGaD
Maraviroc—Pruritus—Etoposide—prostate cancer	4.31e-05	0.000184	CcSEcCtD
Maraviroc—CCR5—Disease—MDM2—prostate cancer	4.3e-05	0.000449	CbGpPWpGaD
Maraviroc—Shock—Prednisone—prostate cancer	4.3e-05	0.000183	CcSEcCtD
Maraviroc—Nervous system disorder—Prednisone—prostate cancer	4.29e-05	0.000182	CcSEcCtD
Maraviroc—Decreased appetite—Capecitabine—prostate cancer	4.26e-05	0.000182	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	4.26e-05	0.000444	CbGpPWpGaD
Maraviroc—Alopecia—Epirubicin—prostate cancer	4.25e-05	0.000181	CcSEcCtD
Maraviroc—Skin disorder—Prednisone—prostate cancer	4.24e-05	0.000181	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—prostate cancer	4.24e-05	0.000443	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LEP—prostate cancer	4.24e-05	0.000442	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Capecitabine—prostate cancer	4.24e-05	0.00018	CcSEcCtD
Maraviroc—Fatigue—Capecitabine—prostate cancer	4.23e-05	0.00018	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—prostate cancer	4.21e-05	0.000179	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—prostate cancer	4.21e-05	0.00044	CbGpPWpGaD
Maraviroc—Erythema multiforme—Doxorubicin—prostate cancer	4.21e-05	0.000179	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CAV1—prostate cancer	4.2e-05	0.000438	CbGpPWpGaD
Maraviroc—Constipation—Capecitabine—prostate cancer	4.2e-05	0.000179	CcSEcCtD
Maraviroc—Pain—Capecitabine—prostate cancer	4.2e-05	0.000179	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—prostate cancer	4.19e-05	0.000178	CcSEcCtD
Maraviroc—Erythema—Epirubicin—prostate cancer	4.19e-05	0.000178	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CB—prostate cancer	4.18e-05	0.000437	CbGpPWpGaD
Maraviroc—Diarrhoea—Etoposide—prostate cancer	4.17e-05	0.000178	CcSEcCtD
Maraviroc—Anorexia—Prednisone—prostate cancer	4.17e-05	0.000177	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	4.16e-05	0.000435	CbGpPWpGaD
Maraviroc—Eye disorder—Doxorubicin—prostate cancer	4.16e-05	0.000177	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KDR—prostate cancer	4.15e-05	0.000433	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—prostate cancer	4.14e-05	0.000433	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Docetaxel—prostate cancer	4.14e-05	0.000176	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—prostate cancer	4.13e-05	0.000176	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—prostate cancer	4.13e-05	0.000176	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ESR1—prostate cancer	4.04e-05	0.000422	CbGpPWpGaD
Maraviroc—Angiopathy—Doxorubicin—prostate cancer	4.04e-05	0.000172	CcSEcCtD
Maraviroc—Dizziness—Etoposide—prostate cancer	4.03e-05	0.000172	CcSEcCtD
Maraviroc—Gastrointestinal pain—Capecitabine—prostate cancer	4.01e-05	0.000171	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—prostate cancer	4.01e-05	0.000171	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—prostate cancer	4.01e-05	0.000171	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—prostate cancer	4.01e-05	0.000171	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	4e-05	0.000417	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.99e-05	0.000416	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Prednisone—prostate cancer	3.98e-05	0.00017	CcSEcCtD
Maraviroc—Insomnia—Prednisone—prostate cancer	3.95e-05	0.000168	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—BAD—prostate cancer	3.95e-05	0.000412	CbGpPWpGaD
Maraviroc—Alopecia—Doxorubicin—prostate cancer	3.93e-05	0.000167	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.93e-05	0.000411	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1B—prostate cancer	3.93e-05	0.00041	CbGpPWpGaD
Maraviroc—Paraesthesia—Prednisone—prostate cancer	3.92e-05	0.000167	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—prostate cancer	3.9e-05	0.000166	CcSEcCtD
Maraviroc—Abdominal pain—Capecitabine—prostate cancer	3.88e-05	0.000165	CcSEcCtD
Maraviroc—Body temperature increased—Capecitabine—prostate cancer	3.88e-05	0.000165	CcSEcCtD
Maraviroc—Vomiting—Etoposide—prostate cancer	3.88e-05	0.000165	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—prostate cancer	3.87e-05	0.000165	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—prostate cancer	3.87e-05	0.000165	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—prostate cancer	3.87e-05	0.000165	CcSEcCtD
Maraviroc—Rash—Etoposide—prostate cancer	3.84e-05	0.000164	CcSEcCtD
Maraviroc—Dermatitis—Etoposide—prostate cancer	3.84e-05	0.000164	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APC—prostate cancer	3.82e-05	0.000399	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—prostate cancer	3.82e-05	0.000399	CbGpPWpGaD
Maraviroc—Headache—Etoposide—prostate cancer	3.82e-05	0.000163	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—prostate cancer	3.82e-05	0.000163	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.8e-05	0.000397	CbGpPWpGaD
Maraviroc—Decreased appetite—Prednisone—prostate cancer	3.8e-05	0.000162	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IRS1—prostate cancer	3.78e-05	0.000395	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGF—prostate cancer	3.78e-05	0.000395	CbGpPWpGaD
Maraviroc—Fatigue—Prednisone—prostate cancer	3.77e-05	0.00016	CcSEcCtD
Maraviroc—Syncope—Epirubicin—prostate cancer	3.76e-05	0.00016	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—prostate cancer	3.75e-05	0.00016	CcSEcCtD
Maraviroc—Constipation—Prednisone—prostate cancer	3.74e-05	0.000159	CcSEcCtD
Maraviroc—Hypersensitivity—Docetaxel—prostate cancer	3.73e-05	0.000159	CcSEcCtD
Maraviroc—CCR5—Disease—CTNNB1—prostate cancer	3.71e-05	0.000387	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—prostate cancer	3.68e-05	0.000157	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GSK3B—prostate cancer	3.67e-05	0.000383	CbGpPWpGaD
Maraviroc—Cough—Epirubicin—prostate cancer	3.65e-05	0.000156	CcSEcCtD
Maraviroc—Asthenia—Docetaxel—prostate cancer	3.64e-05	0.000155	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—prostate cancer	3.63e-05	0.000154	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1A—prostate cancer	3.62e-05	0.000378	CbGpPWpGaD
Maraviroc—Nausea—Etoposide—prostate cancer	3.62e-05	0.000154	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—INS—prostate cancer	3.62e-05	0.000378	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—prostate cancer	3.61e-05	0.000377	CbGpPWpGaD
Maraviroc—Hypersensitivity—Capecitabine—prostate cancer	3.61e-05	0.000154	CcSEcCtD
Maraviroc—Pruritus—Docetaxel—prostate cancer	3.58e-05	0.000153	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—prostate cancer	3.58e-05	0.000152	CcSEcCtD
Maraviroc—Gastrointestinal pain—Prednisone—prostate cancer	3.57e-05	0.000152	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—prostate cancer	3.57e-05	0.000152	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—prostate cancer	3.55e-05	0.000151	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CREBBP—prostate cancer	3.54e-05	0.00037	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.54e-05	0.00037	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.54e-05	0.000151	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—prostate cancer	3.52e-05	0.00015	CcSEcCtD
Maraviroc—Asthenia—Capecitabine—prostate cancer	3.52e-05	0.00015	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1—prostate cancer	3.5e-05	0.000365	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.49e-05	0.000365	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—prostate cancer	3.48e-05	0.000364	CbGpPWpGaD
Maraviroc—Syncope—Doxorubicin—prostate cancer	3.47e-05	0.000148	CcSEcCtD
Maraviroc—Pruritus—Capecitabine—prostate cancer	3.47e-05	0.000148	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—prostate cancer	3.47e-05	0.000148	CcSEcCtD
Maraviroc—Diarrhoea—Docetaxel—prostate cancer	3.47e-05	0.000148	CcSEcCtD
Maraviroc—Abdominal pain—Prednisone—prostate cancer	3.45e-05	0.000147	CcSEcCtD
Maraviroc—Body temperature increased—Prednisone—prostate cancer	3.45e-05	0.000147	CcSEcCtD
Maraviroc—CCR5—Disease—EP300—prostate cancer	3.45e-05	0.00036	CbGpPWpGaD
Maraviroc—Oedema—Epirubicin—prostate cancer	3.42e-05	0.000146	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—prostate cancer	3.41e-05	0.000145	CcSEcCtD
Maraviroc—Infection—Epirubicin—prostate cancer	3.4e-05	0.000145	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAP2K1—prostate cancer	3.38e-05	0.000353	CbGpPWpGaD
Maraviroc—Cough—Doxorubicin—prostate cancer	3.38e-05	0.000144	CcSEcCtD
Maraviroc—Shock—Epirubicin—prostate cancer	3.36e-05	0.000143	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—prostate cancer	3.36e-05	0.000351	CbGpPWpGaD
Maraviroc—Convulsion—Doxorubicin—prostate cancer	3.36e-05	0.000143	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.36e-05	0.00035	CbGpPWpGaD
Maraviroc—Diarrhoea—Capecitabine—prostate cancer	3.36e-05	0.000143	CcSEcCtD
Maraviroc—CCR5—Disease—SRC—prostate cancer	3.35e-05	0.00035	CbGpPWpGaD
Maraviroc—Nervous system disorder—Epirubicin—prostate cancer	3.35e-05	0.000143	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—prostate cancer	3.35e-05	0.000143	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—prostate cancer	3.33e-05	0.000348	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—prostate cancer	3.32e-05	0.000347	CbGpPWpGaD
Maraviroc—Skin disorder—Epirubicin—prostate cancer	3.32e-05	0.000141	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.31e-05	0.000346	CbGpPWpGaD
Maraviroc—Myalgia—Doxorubicin—prostate cancer	3.3e-05	0.00014	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KRAS—prostate cancer	3.29e-05	0.000343	CbGpPWpGaD
Maraviroc—Anxiety—Doxorubicin—prostate cancer	3.29e-05	0.00014	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.28e-05	0.000139	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—prostate cancer	3.26e-05	0.000139	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—prostate cancer	3.26e-05	0.000139	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.25e-05	0.000339	CbGpPWpGaD
Maraviroc—Dizziness—Capecitabine—prostate cancer	3.24e-05	0.000138	CcSEcCtD
Maraviroc—CCR5—Disease—STAT3—prostate cancer	3.23e-05	0.000337	CbGpPWpGaD
Maraviroc—Vomiting—Docetaxel—prostate cancer	3.22e-05	0.000137	CcSEcCtD
Maraviroc—Hypersensitivity—Prednisone—prostate cancer	3.22e-05	0.000137	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FGF2—prostate cancer	3.22e-05	0.000336	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.2e-05	0.000334	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—prostate cancer	3.19e-05	0.000136	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—prostate cancer	3.19e-05	0.000136	CcSEcCtD
Maraviroc—Headache—Docetaxel—prostate cancer	3.17e-05	0.000135	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOS3—prostate cancer	3.17e-05	0.000331	CbGpPWpGaD
Maraviroc—Oedema—Doxorubicin—prostate cancer	3.16e-05	0.000135	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	3.16e-05	0.000329	CbGpPWpGaD
Maraviroc—Infection—Doxorubicin—prostate cancer	3.14e-05	0.000134	CcSEcCtD
Maraviroc—Asthenia—Prednisone—prostate cancer	3.14e-05	0.000133	CcSEcCtD
Maraviroc—Vomiting—Capecitabine—prostate cancer	3.12e-05	0.000133	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.11e-05	0.000133	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	3.11e-05	0.000325	CbGpPWpGaD
Maraviroc—Shock—Doxorubicin—prostate cancer	3.11e-05	0.000132	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—prostate cancer	3.1e-05	0.000132	CcSEcCtD
Maraviroc—Rash—Capecitabine—prostate cancer	3.09e-05	0.000132	CcSEcCtD
Maraviroc—Pruritus—Prednisone—prostate cancer	3.09e-05	0.000132	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—prostate cancer	3.09e-05	0.000132	CcSEcCtD
Maraviroc—Dermatitis—Capecitabine—prostate cancer	3.09e-05	0.000132	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—JAK2—prostate cancer	3.08e-05	0.000322	CbGpPWpGaD
Maraviroc—Headache—Capecitabine—prostate cancer	3.07e-05	0.000131	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—prostate cancer	3.07e-05	0.000131	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—prostate cancer	3.07e-05	0.000131	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—RXRA—prostate cancer	3.05e-05	0.000318	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—prostate cancer	3.02e-05	0.000316	CbGpPWpGaD
Maraviroc—Anorexia—Doxorubicin—prostate cancer	3.01e-05	0.000128	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MDM2—prostate cancer	3.01e-05	0.000314	CbGpPWpGaD
Maraviroc—Nausea—Docetaxel—prostate cancer	3.01e-05	0.000128	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—prostate cancer	3e-05	0.000314	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—prostate cancer	3e-05	0.000313	CbGpPWpGaD
Maraviroc—Diarrhoea—Prednisone—prostate cancer	2.99e-05	0.000127	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—prostate cancer	2.97e-05	0.000126	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ERBB2—prostate cancer	2.97e-05	0.00031	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Epirubicin—prostate cancer	2.95e-05	0.000126	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—prostate cancer	2.95e-05	0.000125	CcSEcCtD
Maraviroc—CCR5—Disease—EGFR—prostate cancer	2.94e-05	0.000307	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—COMT—prostate cancer	2.93e-05	0.000306	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—prostate cancer	2.93e-05	0.000306	CbGpPWpGaD
Maraviroc—Pain—Epirubicin—prostate cancer	2.92e-05	0.000124	CcSEcCtD
Maraviroc—Constipation—Epirubicin—prostate cancer	2.92e-05	0.000124	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.92e-05	0.000305	CbGpPWpGaD
Maraviroc—Nausea—Capecitabine—prostate cancer	2.91e-05	0.000124	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.89e-05	0.000302	CbGpPWpGaD
Maraviroc—Dizziness—Prednisone—prostate cancer	2.89e-05	0.000123	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.88e-05	0.000123	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.88e-05	0.000301	CbGpPWpGaD
Maraviroc—Insomnia—Doxorubicin—prostate cancer	2.86e-05	0.000122	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—prostate cancer	2.84e-05	0.000121	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL8—prostate cancer	2.81e-05	0.000294	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Epirubicin—prostate cancer	2.79e-05	0.000119	CcSEcCtD
Maraviroc—Vomiting—Prednisone—prostate cancer	2.78e-05	0.000118	CcSEcCtD
Maraviroc—CCR5—Disease—KRAS—prostate cancer	2.78e-05	0.00029	CbGpPWpGaD
Maraviroc—Rash—Prednisone—prostate cancer	2.76e-05	0.000117	CcSEcCtD
Maraviroc—Dermatitis—Prednisone—prostate cancer	2.75e-05	0.000117	CcSEcCtD
Maraviroc—Decreased appetite—Doxorubicin—prostate cancer	2.75e-05	0.000117	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—prostate cancer	2.75e-05	0.000287	CbGpPWpGaD
Maraviroc—Headache—Prednisone—prostate cancer	2.74e-05	0.000117	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.73e-05	0.000116	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—prostate cancer	2.73e-05	0.000116	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—prostate cancer	2.72e-05	0.000284	CbGpPWpGaD
Maraviroc—Pain—Doxorubicin—prostate cancer	2.7e-05	0.000115	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—prostate cancer	2.7e-05	0.000115	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—prostate cancer	2.7e-05	0.000115	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—prostate cancer	2.7e-05	0.000115	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CASP3—prostate cancer	2.69e-05	0.000281	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—prostate cancer	2.69e-05	0.000281	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.68e-05	0.00028	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—prostate cancer	2.68e-05	0.000279	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.65e-05	0.000276	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—prostate cancer	2.62e-05	0.000274	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—prostate cancer	2.6e-05	0.000271	CbGpPWpGaD
Maraviroc—Nausea—Prednisone—prostate cancer	2.6e-05	0.000111	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—prostate cancer	2.59e-05	0.00011	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CA—prostate cancer	2.55e-05	0.000266	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—prostate cancer	2.55e-05	0.000266	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.54e-05	0.000266	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—prostate cancer	2.54e-05	0.000265	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—prostate cancer	2.53e-05	0.000264	CbGpPWpGaD
Maraviroc—Hypersensitivity—Epirubicin—prostate cancer	2.52e-05	0.000107	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—HAO1—prostate cancer	2.51e-05	0.000262	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.51e-05	0.000262	CbGpPWpGaD
Maraviroc—Abdominal pain—Doxorubicin—prostate cancer	2.5e-05	0.000106	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—prostate cancer	2.5e-05	0.000106	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT1—prostate cancer	2.47e-05	0.000258	CbGpPWpGaD
Maraviroc—Asthenia—Epirubicin—prostate cancer	2.45e-05	0.000104	CcSEcCtD
Maraviroc—Pruritus—Epirubicin—prostate cancer	2.42e-05	0.000103	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EP300—prostate cancer	2.41e-05	0.000252	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SRC—prostate cancer	2.35e-05	0.000245	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—prostate cancer	2.34e-05	9.96e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—prostate cancer	2.33e-05	9.92e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—VEGFA—prostate cancer	2.29e-05	0.000239	CbGpPWpGaD
Maraviroc—Asthenia—Doxorubicin—prostate cancer	2.27e-05	9.66e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STAT3—prostate cancer	2.26e-05	0.000236	CbGpPWpGaD
Maraviroc—Dizziness—Epirubicin—prostate cancer	2.26e-05	9.62e-05	CcSEcCtD
Maraviroc—CCR5—Disease—IL6—prostate cancer	2.26e-05	0.000236	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—prostate cancer	2.24e-05	9.53e-05	CcSEcCtD
Maraviroc—Vomiting—Epirubicin—prostate cancer	2.17e-05	9.25e-05	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—prostate cancer	2.16e-05	9.21e-05	CcSEcCtD
Maraviroc—Rash—Epirubicin—prostate cancer	2.15e-05	9.18e-05	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—prostate cancer	2.15e-05	9.17e-05	CcSEcCtD
Maraviroc—Headache—Epirubicin—prostate cancer	2.14e-05	9.12e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—prostate cancer	2.1e-05	0.00022	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—prostate cancer	2.1e-05	0.000219	CbGpPWpGaD
Maraviroc—Dizziness—Doxorubicin—prostate cancer	2.09e-05	8.9e-05	CcSEcCtD
Maraviroc—CCR5—Disease—AKT1—prostate cancer	2.08e-05	0.000217	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—prostate cancer	2.06e-05	0.000215	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADI1—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GRHL1—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CSAD—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSAT1—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CBR1—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TST—prostate cancer	2.05e-05	0.000214	CbGpPWpGaD
Maraviroc—Nausea—Epirubicin—prostate cancer	2.03e-05	8.64e-05	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—prostate cancer	2.01e-05	8.56e-05	CcSEcCtD
Maraviroc—Rash—Doxorubicin—prostate cancer	1.99e-05	8.49e-05	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—prostate cancer	1.99e-05	8.48e-05	CcSEcCtD
Maraviroc—Headache—Doxorubicin—prostate cancer	1.98e-05	8.43e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—prostate cancer	1.94e-05	0.000203	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.9e-05	0.000199	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.9e-05	0.000199	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CKMT2—prostate cancer	1.9e-05	0.000199	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GRHPR—prostate cancer	1.9e-05	0.000199	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—prostate cancer	1.88e-05	8e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—NAGLU—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AOX1—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PGAM2—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM3—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RFK—prostate cancer	1.79e-05	0.000187	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—prostate cancer	1.79e-05	0.000186	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—prostate cancer	1.73e-05	0.00018	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AMACR—prostate cancer	1.7e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.7e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.7e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT1—prostate cancer	1.7e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DEGS1—prostate cancer	1.7e-05	0.000177	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.62e-05	0.000169	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—prostate cancer	1.58e-05	0.000165	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—prostate cancer	1.46e-05	0.000152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.44e-05	0.000151	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGD—prostate cancer	1.44e-05	0.000151	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.36e-05	0.000142	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.32e-05	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTAP—prostate cancer	1.32e-05	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.29e-05	0.000134	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.29e-05	0.000134	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACSL4—prostate cancer	1.23e-05	0.000128	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.23e-05	0.000128	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UMPS—prostate cancer	1.18e-05	0.000123	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ARG2—prostate cancer	1.18e-05	0.000123	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PHGDH—prostate cancer	1.18e-05	0.000123	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LDHB—prostate cancer	1.15e-05	0.00012	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.13e-05	0.000118	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PDHA1—prostate cancer	1.09e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA3—prostate cancer	1.09e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UCP3—prostate cancer	1.09e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TCN2—prostate cancer	1.09e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.04e-05	0.000109	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.04e-05	0.000109	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.99e-06	0.000104	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA4—prostate cancer	9.99e-06	0.000104	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA2—prostate cancer	9.74e-06	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG5—prostate cancer	9.62e-06	0.0001	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SULT1A1—prostate cancer	9.62e-06	0.0001	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA1—prostate cancer	9.4e-06	9.81e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTO1—prostate cancer	9.29e-06	9.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD3B2—prostate cancer	9.29e-06	9.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT2—prostate cancer	9.29e-06	9.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LRP2—prostate cancer	8.91e-06	9.3e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.91e-06	9.3e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLCB2—prostate cancer	8.91e-06	9.3e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—P4HB—prostate cancer	8.74e-06	9.12e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC22A1—prostate cancer	8.5e-06	8.87e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SULT2A1—prostate cancer	8.28e-06	8.65e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MED12—prostate cancer	8.15e-06	8.51e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNG5—prostate cancer	8.08e-06	8.44e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA3—prostate cancer	7.79e-06	8.13e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGDS—prostate cancer	7.43e-06	7.75e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2C19—prostate cancer	7.38e-06	7.71e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—prostate cancer	7.2e-06	7.52e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACHE—prostate cancer	7.2e-06	7.52e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2A6—prostate cancer	7.12e-06	7.43e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.93e-06	7.23e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PRKACB—prostate cancer	6.89e-06	7.19e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.82e-06	7.12e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA2—prostate cancer	6.5e-06	6.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—prostate cancer	6.2e-06	6.47e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2E1—prostate cancer	6.06e-06	6.32e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NQO1—prostate cancer	5.99e-06	6.25e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TH—prostate cancer	5.9e-06	6.16e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.74e-06	5.99e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GGT1—prostate cancer	5.56e-06	5.8e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA1—prostate cancer	5.48e-06	5.72e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.4e-06	5.63e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RXRA—prostate cancer	5.21e-06	5.44e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COMT—prostate cancer	5.02e-06	5.24e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—prostate cancer	4.99e-06	5.21e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ITPR1—prostate cancer	4.91e-06	5.13e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—prostate cancer	4.64e-06	4.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—prostate cancer	4.59e-06	4.79e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPL—prostate cancer	4.5e-06	4.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.35e-06	4.54e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—prostate cancer	4.31e-06	4.5e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—prostate cancer	4.06e-06	4.23e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARA—prostate cancer	3.98e-06	4.15e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAV1—prostate cancer	3.74e-06	3.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.41e-06	3.56e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—INS—prostate cancer	3.23e-06	3.37e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CREBBP—prostate cancer	3.16e-06	3.3e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—prostate cancer	3e-06	3.13e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—prostate cancer	2.83e-06	2.95e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.61e-06	2.73e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—prostate cancer	2.59e-06	2.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—prostate cancer	2.26e-06	2.36e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EP300—prostate cancer	2.15e-06	2.25e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.59e-06	1.66e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—prostate cancer	1.3e-06	1.36e-05	CbGpPWpGaD
